

Drug combo doesn't lengthen glioblastoma survival

November 17 2017



(HealthDay)—In patients with progressive glioblastoma, treatment with

lomustine plus bevacizumab does not confer a survival advantage over treatment with lomustine alone, according to a study published online Nov. 15 in the *New England Journal of Medicine*.

Wolfgang Wick, M.D., from the University of Heidelberg in Germany, and colleagues randomly assigned patients with progression after chemoradiation (2-to-1 ratio) to receive lomustine plus bevacizumab (combination group, n = 288) or lomustine alone (monotherapy group, n = 149 patients).

The researchers found that the median overall survival was 9.1 months in the combination group and 8.6 months in the monotherapy group (hazard ratio for death, 0.95; 95 percent confidence interval, 0.74 to 1.21; P = 0.65). However, locally assessed progression-free survival was 2.7 months longer in the combination group than in the monotherapy group (hazard ratio for [disease progression](#) or death, 0.49; 95 percent confidence interval, 0.39 to 0.61; P patients in the monotherapy group. Neither health-related quality of life nor neurocognitive function was affected by adding bevacizumab to lomustine.

"The effect on progression-free survival was not associated with an increase in overall survival, and [combination therapy](#) was associated with increased toxicity," conclude the authors.

Several authors disclosed financial ties to the pharmaceutical industry, including F. Hoffmann-La Roche, which provided funding for the study.

More information: [Abstract/Full Text \(subscription or payment may be required\)](#)

Copyright © 2017 [HealthDay](#). All rights reserved.

Citation: Drug combo doesn't lengthen glioblastoma survival (2017, November 17) retrieved 6 May 2024 from <https://medicalxpress.com/news/2017-11-drug-combo-doesnt-lengthen-glioblastoma.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.